Drug Database
AB

abiraterone acetate (Yonsa)

✓ Approved

Sun Pharmaceutical Industries Ltd. · CYP17A1 · Small Molecule

What is abiraterone acetate?

abiraterone acetate is a small molecule developed by Sun Pharmaceutical Industries Ltd.. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesYonsa
CompanySun Pharmaceutical Industries Ltd.
Drug ClassSmall Molecule
Molecular TargetCYP17A1
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Sun Pharmaceutical Industries Ltd.

Mechanism of Action

Molecular Targets

abiraterone acetate acts on 1 molecular target:

CYP17A1cytochrome P450 family 17 subfamily A member 1 (CYP17, S17AH)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

abiraterone acetate is developed for 2 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Prostate cancer✓ Approved
Renal and urinary disordersGenitourinary symptomPhase I

Related Research Articles

PubMedSeminars in oncology2026-09-19

Rhabdomyolysis resulting from the interaction of rosuvastatin and abiraterone: A case study.

Blagojevic Christina C, Kim Richard B RB, Juurlink David N DN, Zipursky Jonathan S JS

Abiraterone is a first-line therapy for metastatic castrate-resistant prostate cancer. In vitro, abiraterone metabolites inhibit OATP1B1, the primary hepatic uptake transporter for several substrates, including statins. We describe the case of a 70-year-old man taking rosuvastatin who commenced treatment with abiraterone for metastatic castrate-resistant prostate cancer. Two months later, he presented to hospital with nonspecific symptoms including fatigue and diffuse myalgias with laboratory evidence of rhabdomyolysis and associated acute kidney injury. Plasma rosuvastatin concentrations were more than 40-fold higher than expected for the dose. Subsequent pharmacogenetic testing showed the patient was heterozygous for SLCO1B1*15, a variant of the SLCO1B1 gene encoding OATP1B1, which results in moderately reduced OATP1B1 transport activity. Considering the high frequency of statin prescribing, clinicians should be aware of the possible drug-drug interactions between statins and abiraterone and the associated risk of rhabdomyolysis, which is also affected by genetic differences.

PMID 42762808
Read full article →
PubMedJournal of chromatography. A2026-09-19

Investigation of the retention mechanism of abiraterone and its metabolites on ODS stationary phases using computational chemistry.

Haginaka Jun J, Honda Chie C, Horiyama Shizuyo S, Hayama Noboru N et al.

Retention mechanisms of abiraterone (Abi, Abi1) and its metabolites [Δ4-Abi (D4A, Ab2), 3-keto-5α-Abi (Abi3), 3β-OH-5α-Abi (Abi4), 3α-OH-5α-Abi (Abi5), 3-keto-5β-Abi (Abi6), 3β-OH-5β-Abi (Abi7), 3α-OH-5β-Abi (Abi8) and 3α-OH-Abi (Abi9) on monomeric and polymeric ODS stationary phases were investigated using computational chemistry. Abi1/Abi9, Abi4/Abi5, Abi7/Abi8 and Abi3/Abi6 are pairs of diastereomers. The 1,3-diaxial interactions involving the C3‑hydroxy groups in Abi9, Abi5 and Abi8 appear to hinder hydration, leading to less favorable solvation and greater hydrophobicity than their corresponding diastereomers. Therefore, on monomeric ODS stationary phases, the elution orders were Abi1 < Abi9, Abi4 < Abi5, Abi7 < Abi8 and Abi3 ≈ Abi6, in agreement with the corresponding order of hydrophobicity. In contrast, on polymeric ODS stationary phases, the elution orders were Abi9 < Abi1, Abi5 < Abi4, Abi8 < Abi7 and Abi6 < Abi3. This reversal is likely attributable to the planarity recognition capability of the polymeric ODS stationary phase. On monomeric ODS stationary phases, the van der Waals interaction energies between Abi and its eight metabolites (Abi2 - Abi9) and the monomeric C12 stationary phase, calculated using the MM2 force field, showed a good correlation with their log k values. Furthermore, for six compounds bearing a C3‑hydroxyl group (Abi1/Abi9, Abi4/Abi5 and Abi7/Abi8), the hydration free energies calculated by the DFT/SMD method also showed a good correlation with their log k values.

PMID 42762703
Read full article →
PubMedInternational journal of clinical oncology2026-09-19

Prognostic impact of diabetes or hypertension in smokers with CRPC receiving enzalutamide or abiraterone.

Fukagai Takashi T, Izumi Kouji K, Yamagishi Motoki M, Shima Takashi T et al.

Smoking and lifestyle‑related diseases increase the risk of cancer incidence and progression, but their impact on castration‑resistant prostate cancer (CRPC) remains unclear. This study examined whether diabetes mellitus (DM), hypertension (HT), and smoking habit (SH) affect the prognosis of CRPC patients treated with enzalutamide (ENZ) or abiraterone plus prednisolone (ABI). Using data from the ENABLE study for PCa, an investigator‑initiated, multicenter, randomized controlled trial, patients were retrospectively categorized into two groups based on SH. Subsequently, the impact of the absence or presence of either DM or HT and treatment arm (ENZ or ABI) on survival endpoints was investigated. A total of 178 patients were randomized and treated, of whom 161 had available SH information and were included in the analysis (84 SH- and 77 SH+). No significant differences in survival endpoints were observed between the SH- and SH+ groups. In the SH+ group, prostate cancer-specific survival (PCSS) was significantly worse in the with‑DM/HT group than in the no‑DM/HT group (p = 0.0215). Multivariate Cox analysis confirmed that the presence of DM or HT was an independent predictor of poor PCSS. Furthermore, a significant difference in PCSS between the no‑DM/HT and with‑DM/HT groups was observed in the ENZ arm (p = 0.0201), but not in the ABI arm. SH does not appear to influence the efficacy of ENZ or ABI therapy for CRPC; however, among SH+ patients, the presence of DM or HT was associated with poorer survival outcomes, particularly in those treated with ENZ.

PMID 42762423
Read full article →
PubMedJournal of complementary & integrative medicine2026-09-19

In vitro, in vivo, and computational evaluation of xanthine oxidase inhibitory and antihyperuricemic activities of Piper betle L. ethyl acetate fraction.

Hao Bui Thi BT, Minh Phan Hong PH, Anh Hong Nguyen Thi NT, Nhat Hoang Nam HN et al.

Gout is a metabolic disorder characterized by hyperuricemia and urate crystal deposition. This study evaluated the xanthine oxidase inhibitory, antihyperuricemic, anti-inflammatory, analgesic, and in silico target-binding properties of an EtOAc fraction of Piper betle L. aerial parts. P. betle aerial parts were extracted with ethanol and partitioned to obtain an EtOAc fraction. Xanthine oxidase inhibition was evaluated spectrophotometrically, and antihyperuricemic activity was examined in potassium oxonate-treated mice given the fraction (200 or 600 mg/kg). Carrageenan-induced paw edema and acetic acid-induced writhing were used to assess anti-inflammatory and analgesic effects. Hydroxychavicol was docked with xanthine oxidase, cyclooxygenase-2, and transient receptor potential vanilloid 1, followed by molecular dynamics simulations. The ethyl acetate fraction inhibited xanthine oxidase with an IC50 of 4.28 ± 0.15 μg/mL, whereas allopurinol showed an IC50 of 1.06 ± 0.07 μg/mL. In hyperuricemic mice, serum uric acid showed a decreasing trend, and urinary uric acid was significantly reduced at 600 mg/kg. Paw edema was reduced at 600 mg/kg, whereas writhing responses were not significantly inhibited. Docking predicted favorable hydroxychavicol binding to the three targets, but molecular dynamics indicated weaker ligand retention in the xanthine oxidase complex than in the cyclooxygenase-2 and transient receptor potential vanilloid 1 complexes. The ethyl acetate fraction of P. betle demonstrated preclinical xanthine oxidase inhibitory, urate-lowering, and anti-inflammatory potential. Stronger chemical standardization and mechanistic validation are required before therapeutic relevance can be inferred.

PMID 42762091
Read full article →
PubMedFood chemistry: X2026-09-19

Key aroma contributors and perceptual interactions of dried longan-like aroma in lapsang souchong black tea with different natural aging times.

Shi Yutao Y, Zuo Lirong L, Huang Canyang C, Zhou Yanhua Y et al.

This study investigated aroma evolution in Lapsang Souchong black tea (LS) with different natural aging times and the perceptual basis of its dried longan-like aroma. Sensory evaluation, HS-SPME-GC-MS, aroma recombination/omission, S-curve-Feller analysis, and molecular simulations showed that, with increasing natural aging time, LS aroma shifted from pine-smoke, sweet, and fruity aroma dominance to prominent dried longan-like aroma, followed by enhanced woody and aged aromas. LS19 showed the highest dried longan-like aroma intensity. Benzaldehyde, Geranyl acetate, and 2-Acetylfuran were identified as key contributors. Binary mixtures mainly showed additive effects, whereas the ternary system exhibited a synergistic effect. Molecular simulations suggested stable binding of the key aroma compounds with the candidate olfactory receptor OR1A1 (-53.89 kcal/mol), with ILE126 and VAL227 identified as key binding residues. These findings clarify the material basis and perceptual features of dried longan-like aroma and support LS quality evaluation, storage management, and aroma regulation.

PMID 42761899
Read full article →
PubMedResearch in veterinary science2026-09-19

Melatonin testicular synthesis and its role in reproductive physiology in seasonal and non-seasonal breeders.

Cesauri Mattia M, Ventrella Domenico D, Fanelli Diana D, Elmi Alberto A

Melatonin (MT) is an indoleamine primarily produced by the pineal gland in a light-dark-dependent manner; however, it is also locally synthesized in the testis, where it influences male reproductive physiology upon interaction with its receptors (MT1/MT2), the binding started the bio-signaling inside the cells mediated by MT. This review outlines the intratesticular effects of MT, addressing seasonal and non-seasonal mammals. In rodents, Leydig, Sertoli, and germ cells contain enzymatic machinery to produce MT, with MT1/MT2 signaling influencing androgen production through cAMP-dependent and independent pathways and interacting with local Corticotropin-Releasing Hormone (CRH), serotoninergic, and catecholaminergic systems to regulate steroidogenesis and testicular plasticity. In non-seasonal species, Sertoli cells express MT1/MT2 and react to melatonin through alterations in proliferation, expression of spermatogenesis-related genes, and restructuring of glycolytic and acetate metabolism, thus modifying energetic support to germ cells. In seasonal breeders like rams and roe deer, MT1/MT2, N-acetyltransferase (AANAT), and acetylserotonin O-methyltransferase (ASMT) are found in testicular cells, spermatozoa, and the epididymis. Exogenous MT treatments are linked to advancements in the breeding season, increased testicular size and enhanced testosterone secretion in rams. MT1/MT2 were reported in spermatozoa from several seasonal and non-seasonal mammalian species and MT frequently was detected in seminal plasma, where they are involved in motility, capacitation, cryotolerance, and antioxidant protection. Therefore, suggesting that MT serves as a conserved but diversified intratesticular signal that integrates photoperiodic, metabolic, and cytoprotective regulation of male fertility.

PMID 42762694
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about abiraterone acetate